Docoh
Loading...
Sign up Log in

BCRX Biocryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.

Company profile

Ticker
BCRX
Exchange
NASDAQ
Website
www.biocryst.com
CEO
Jon Stonehouse
Employees
Incorporated
Delaware
Location
North Carolina
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Denali Therapeutics • Exelixis ...
SEC CIK
0000882796
Corporate docs
IRS number
621413174

BCRX stock data

(
)

News

Pro users get this 30m faster
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
30 Jul 21
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $16.34.
Analyzing BioCryst Pharmaceuticals's Unusual Options Activity
29 Jul 21
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares experienced unusual options activity on Thursday. The stock price moved up to $16.93 following the option alert.
Unusual Options Activity Insight: BioCryst Pharmaceuticals
23 Jul 21
On Friday, shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw unusual options activity. After the option alert, the stock price moved up to $17.1.
BioCryst Pharmaceuticals Files For U.S. Patent Application Titled, 'SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS'
22 Jul 21
BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
15 Jul 21

Press releases

Pro users get this 30m faster
BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH
15 Jul 21
RESEARCH TRIANGLE PARK, N.C., July 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the designs for REDEEM-1 and REDEEM-2, two upcoming pivotal trials with its oral Factor D
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
10 Jul 21
RESEARCH TRIANGLE PARK, N.C., July 10, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that hereditary angioedema (HAE) patients who were randomized to receive 150 mg of oral,
ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress
1 Jul 21
RESEARCH TRIANGLE PARK, N.C., July 01, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
12 May 21
Thinking about buying stock in At Home Group, Himax Technologies, Trevena, BioCryst Pharmaceuticals, or Zynga?
6 May 21

Calendar

7 May 21
2 Aug 21
31 Dec 21

Financial summary

Financial statements Chart BCRX financial data
Quarter (USD)
 Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 226.9M 226.9M 226.9M 226.9M 226.9M 226.9M
Cash burn (monthly) 15.08M (positive/no burn) 17.13M 15.43M 20.34M 14.58M
Cash used (since last report) 61.77M n/a 70.17M 63.22M 83.33M 59.74M
Cash remaining 165.13M n/a 156.73M 163.68M 143.57M 167.16M
Runway (months of cash) 11.0 n/a 9.2 10.6 7.1 11.5

Beta Read what these cash burn values mean

Recent insider trades

BCRX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 Jul 21 Milano Vincent NQSO Common Stock Grant Aquire A No No 17.25 66,667 1.15M 66,667
15 Jul 21 Abercrombie George B Common Stock Sell Dispose S No Yes 15.69 5,000 78.45K 3,000
15 Jul 21 Abercrombie George B Common Stock Option exercise Aquire M No Yes 2.63 5,000 13.15K 8,000
15 Jul 21 Abercrombie George B NQSO Common Stock Option exercise Dispose M No Yes 2.63 5,000 13.15K 5,000
10 Jun 21 Nancy J Hutson Common Stock Sell Dispose S No Yes 16.86 23,333 393.39K 65,073
10 Jun 21 Nancy J Hutson Common Stock Option exercise Aquire M No Yes 3.32 15,000 49.8K 88,406
10 Jun 21 Nancy J Hutson Common Stock Option exercise Aquire M No Yes 2.85 8,333 23.75K 73,406
10 Jun 21 Nancy J Hutson Automatic Stock Option Grant Common Stock Option exercise Dispose M No Yes 3.32 15,000 49.8K 0
10 Jun 21 Nancy J Hutson NQSO Common Stock Option exercise Dispose M No Yes 2.85 8,333 23.75K 0
28 May 21 Steve Aselage Common Stock Grant Aquire A No No 15.77 634 10K 32,130
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

BCRX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

58.8% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 191 177 +7.9%
Opened positions 47 40 +17.5%
Closed positions 33 16 +106.3%
Increased positions 55 56 -1.8%
Reduced positions 69 56 +23.2%
13F shares
 Current Prev Q Change
Total value 1.37B 999.53M +37.3%
Total shares 104.51M 120.63M -13.4%
Total puts 1.94M 1.15M +69.4%
Total calls 2.84M 1.26M +125.7%
Total put/call ratio 0.7 0.9 -24.9%
Largest owners
 Shares Value Change
BLK Blackrock 16.24M $165.18M -0.1%
Baker Bros. Advisors 12.71M $129.27M +0.1%
Vanguard 9.7M $98.65M -16.4%
Sarissa Capital Management 7.64M $77.68M -6.6%
STT State Street 7.31M $74.33M -33.9%
HealthCor Management 4.89M $49.7M NEW
Artisan Partners Limited Partnership 3.03M $30.77M NEW
Geode Capital Management 2.99M $30.41M +12.6%
Deerfield Management 2.61M $26.5M -55.4%
Nuveen Asset Management 2.5M $25.47M +59.3%
Largest transactions
 Shares Bought/sold Change
Citadel Advisors 807.61K -5.69M -87.6%
HealthCor Management 4.89M +4.89M NEW
STT State Street 7.31M -3.75M -33.9%
Point72 Asset Management 0 -3.23M EXIT
Deerfield Management 2.61M -3.23M -55.4%
Artisan Partners Limited Partnership 3.03M +3.03M NEW
Marshall Wace North America 865.54K -1.93M -69.1%
Vanguard 9.7M -1.9M -16.4%
GS Goldman Sachs 2.17M +1.87M +614.9%
IVZ Invesco 1.43M +1.4M +3766.7%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Regeneron Pharmaceuticals • Arrowhead Pharmaceuticals • Roche • La Jolla Pharmaceutical • Shire • Achillion Pharmaceuticals • Medicines • Chugai Pharmaceutical • Alnylam Pharmaceuticals • KalVista Pharmaceuticals
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: activin, adjudication, adolescent, Athyrium, Autorisation, capped, Cautionary, center, Codification, constrained, contemporaneously, conversion, count, covenant, Cure, defective, depict, drawn, EC, extinguishment, focusing, France, freight, French, front, Germany, heading, hereof, impute, imputed, inclusive, indeterminate, intake, Intermediate, Ireland, leaseback, lessee, linear, mandated, mix, NaN, negligent, NHI, obligor, opsonization, payoff, PERAMIFLU, pharmacy, PIK, prepaid, prepay, principle, prophylactic, RABIVAB, reader, refer, reference, repurchase, reticulocyte, RPI, runway, Secretary, Simplifying, specialty, step, stoppage, suggested, sum, symptomatic, Temporaire, thereon, timeframe, turn, unamortized, unaudited, uncomplicated, unintentional, unrelated, unsold, voluntary
Removed: accept, actively, alleviate, ALPIVAB, amending, anticipation, arbitrator, ascending, Asia, Australasia, biopharmaceutical, Brazil, Brazilian, broader, Callaghan, Canadian, Carbohydrate, caution, CDC, centralized, characterize, clarified, closed, collected, combination, Commencing, commercialized, compound, concept, confirmed, constitute, convey, depository, designation, discharge, dissolve, dosed, doubt, eculizumab, effectuate, endpoint, exceeded, experimental, expressed, fashion, Ferrier, floating, forecast, formal, formed, fulfilling, Goodwill, hemorrhagic, hosting, impacting, IND, indirectly, inhibition, Innovation, Innovative, investigational, kallikrein, largest, line, liquidate, liquidating, MAA, MAD, mark, materialize, MDCP, modify, mortality, move, Nacional, nation, novation, observed, opened, oversee, PCR, PD, peak, pending, pharmacodynamic, pharmacokinetic, PK, post, posted, presidential, projecting, Promising, promoting, proof, prospect, qualitative, randomized, ravulizumab, reaction, redeemable, redeemed, redemption, refinanced, remdesivir, repeal, replaced, respiratory, restating, revise, ROFN, rulemaking, Sakigake, seasonality, stream, substitution, Subtopic, supportable, threshold, Trump, ulodesine, unanticipated, unchanged, uncured, undetectable, unfold, User, validated, Victoria, volume, VUW, Wellington, wholly
From filing 10-Q 2021 Q1

Financial reports

View all
10-Q
2021 Q1
Quarterly report
7 May 21
10-K
2020 FY
Annual report
1 Mar 21
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
9 Aug 20
10-Q
2020 Q1
Quarterly report
10 May 20
10-K
2019 FY
Annual report
13 Mar 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
14 Mar 19

Current reports

View all
8-K
BioCryst Appoints Vincent Milano to Board of Directors
28 Jul 21
8-K
BioCryst Launches ORLADEYO™ (berotralstat) in Germany
3 Jun 21
8-K
Departure of Directors or Certain Officers
26 May 21
8-K
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
12 May 21
8-K
BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones
6 May 21
8-K
Regulation FD Disclosure
30 Apr 21
8-K
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
14 Apr 21
8-K
Regulation FD Disclosure
26 Mar 21
8-K
Regulation FD Disclosure
22 Mar 21
8-K
Regulation FD Disclosure
18 Mar 21

Registration and prospectus

View all
S-8
Registration of securities for employees
28 May 21
S-8
Registration of securities for employees
28 May 21
S-3ASR
Automatic shelf registration
1 Mar 21
S-8
Registration of securities for employees
12 Aug 20
S-8
Registration of securities for employees
10 Jun 20
S-8
Registration of securities for employees
10 Jun 20
S-8
Registration of securities for employees
10 Jun 20
424B2
Prospectus for primary offering
29 May 20
424B5
Prospectus supplement for primary offering
27 May 20
S-3
Shelf registration
24 Apr 20

Proxies

View all
DEFA14A
Additional proxy soliciting materials
13 Apr 21
DEF 14A
Definitive proxy
13 Apr 21
DEFA14A
Additional proxy soliciting materials
31 Mar 20
DEF 14A
Definitive proxy
31 Mar 20
PRE 14A
Preliminary proxy
19 Mar 20
DEFA14A
Additional proxy soliciting materials
17 Apr 19
DEF 14A
Definitive proxy
17 Apr 19
DEF 14A
Definitive proxy
28 Sep 18
PRE 14A
Preliminary proxy
17 Sep 18
DEFM14A
Proxy related to merger
30 May 18

Other

View all
EFFECT
Notice of effectiveness
15 May 20
CORRESP
Correspondence with SEC
11 May 20
CORRESP
Correspondence with SEC
3 May 20
CT ORDER
Confidential treatment order
1 May 20
UPLOAD
Letter from SEC
26 Apr 20
CT ORDER
Confidential treatment order
17 Dec 18
CT ORDER
Confidential treatment order
6 Jun 18
CT ORDER
Confidential treatment order
5 Apr 18
EFFECT
Notice of effectiveness
11 Dec 17
CORRESP
Correspondence with SEC
7 Dec 17

Ownership

View all
4
BIOCRYST PHARMACEUTICALS / VINCENT MILANO ownership change
28 Jul 21
3
BIOCRYST PHARMACEUTICALS / VINCENT MILANO ownership change
28 Jul 21
4
BIOCRYST PHARMACEUTICALS / GEORGE B ABERCROMBIE ownership change
19 Jul 21
4
BIOCRYST PHARMACEUTICALS / Nancy J Hutson ownership change
14 Jun 21
4
BIOCRYST PHARMACEUTICALS / William P Sheridan ownership change
1 Jun 21
4
BIOCRYST PHARMACEUTICALS / ROBERT ALEXANDER INGRAM ownership change
1 Jun 21
4
BIOCRYST PHARMACEUTICALS / Nancy J Hutson ownership change
1 Jun 21
4
BIOCRYST PHARMACEUTICALS / THERESA HEGGIE ownership change
1 Jun 21
4
BIOCRYST PHARMACEUTICALS / STEVE ASELAGE ownership change
1 Jun 21
4
BIOCRYST PHARMACEUTICALS / ALAN G LEVIN ownership change
27 May 21

Patents

View all
APP
Utility
Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors
22 Jul 21
Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
GRANT
Utility
Human plasma kallikrein inhibitors
20 Jul 21
Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Lakshminarayana Vogeti
APP
Utility
Prodrugs of Kallikrein Inhibitors
1 Jul 21
Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Venkat R. Chintareddy, Weihe Zhang, Lakshminarayana Vogeti
APP
Utility
Methods and Compositions for Treatment of Zika Virus Infection
24 Jun 21
The present disclosure is directed to methods and compositions that are useful in combating the spread of Zika virus infections, such as, but not limited to, methods and compositions for treating, preventing or suppressing a Zika virus infection in a subject.
GRANT
Utility
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
1 Jun 21
Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman

Transcripts

View all
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
25 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q4
Earnings call transcript
5 Mar 20
2019 Q3
Earnings call transcript
6 Nov 19
2019 Q2
Earnings call transcript
6 Aug 19
2019 Q1
Earnings call transcript
8 May 19
2018 Q4
Earnings call transcript
4 Mar 19

Reddit threads

View all